TABLE 1.
Protein | LC50 (μg/ml) | Relative potency | 95% fiducial limits of relative potency
|
Slope ± SE | Intercept ± SE | |
---|---|---|---|---|---|---|
Lower | Upper | |||||
Cry1Ia | 21.13 | 0.052 | 0.04 | 0.06 | 3.25 ± 0.35 | 0.71 ± 0.47 |
Cry1Da | 4.94 | 0.22 | 0.16 | 0.31 | 1.66 ± 0.16 | 3.85 ± 0.12 |
Cry1Ac | 1.09 | 1.00 | 1.87 ± 0.17 | 4.92 ± 0.06 | ||
Cry1Ba | 1.03 | 1.11 | 0.84 | 1.42 | 1.53 ± 0.17 | 4.98 ± 0.07 |
Cry9Ca | 0.39 | 2.78 | 2.32 | 3.35 | 3.67 ± 0.31 | 6.49 ± 0.14 |
Cry1Ab | 0.45 | 2.41 | 1.80 | 3.23 | 1.29 ± 0.13 | 5.44 ± 0.07 |
Parameters were obtained from the POLO-PC program (27). The χ2 value was not significant (P > 0.05) for a goodness-of-fit test for each regression. Slopes could not be fitted in parallel. The relative potency was expressed as the ratio of the LC50 value for each Cry protein to the LC50 value for Cry1Ac (39).